Photo from Margherita Ambrosini/X
May 24, 2024, 00:14
Margherita Ambrosini: Rare and important subgroup of POLE/D1 proofreading deficient (pd) mCRC treated with ICIs across Europe, USA and Israel
Margherita Ambrosini, Medical Oncology resident at University of Milan, shared on X/Twitter:
“Excited and honored to can finally share our work about the rare and important subgroup of POLE/D1 proofreading deficient (pd) mCRC treated with ICIs across Europe, USA and Israel.
POLE/D1pd define a small (~1%) subgroup of ultramutated mCRC with excellent immune-sensitivity.
89% ORR
2y PFS 88% – 2y OS 86%.
Even higher than dMMR/MSI-H mCRC treated with ICIs – even after adjustment for baseline prognostic factors.
Who?
male sex
young age
POLD1 right sided, POLE right and left sided
atypical RAS mutations
exceptionally high TMB.
Possible cohexistence with dMMR/MSI-H status.
Crucial the selection of a proofreading deficient variant – TMB can help!”
Source: Margherita Ambrosini/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56
Nov 13, 2024, 15:46
Nov 13, 2024, 15:32
Nov 13, 2024, 15:29